A Phase 1, Open-label, Single Dose, Parallel-cohort Study To Evaluate The Pharmacokinetics Of Palbociclib (Pd-0332991) In Subjects With Impaired Hepatic Function

Trial Profile

A Phase 1, Open-label, Single Dose, Parallel-cohort Study To Evaluate The Pharmacokinetics Of Palbociclib (Pd-0332991) In Subjects With Impaired Hepatic Function

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Palbociclib (Primary)
  • Indications Breast cancer; Colorectal cancer; Glioblastoma; Liposarcoma; Malignant melanoma; Mantle-cell lymphoma; Multiple myeloma; Non-small cell lung cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Nov 2016 Status changed from recruiting to completed.
    • 04 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 Nov 2016.
    • 04 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top